Trial document

This study has been imported from without additional data checks.
drksid header


Trial Description

start of 1:1-Block title


A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

SMP-986 is a compound being developed for the treatment of overactive bladder syndrome
(OABS). This clinical study is designed to test the hypothesis that SMP-986 at doses of
20mg, 40mg, 80mg or 120mg provides greater symptom relief in OABS compared to placebo. The
hypothesis will be tested by measuring the change in mean voids/24 hrs after treatment with
SMP-986 compared to placebo, as well comparing the change in: the severity of urgency
episodes, mean number of urgency episodes/24 hr, mean number of incontinence episodes/24 hr
and the mean void volume/void between SMP-986 and placebo.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

A multicenter study conducted in patients with OABS comprising a 2-week single blind placebo
run-in period followed by an 8-week randomized, double-blind, placebo controlled treatment
period with patients randomized to receive 20 mg, 40 mg, 80 mg or 120 mg SMP 986 or placebo
in a 1:1:1:1:1 ratio in parallel groups on an outpatient basis with study center visits.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?


end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:


end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00004137
  •   2012/10/17
  •   2006/12/08
  •   no
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   NCT00409539  (
  •   D3601113  (Dainippon Sumitomo Pharma Europe LTd.)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Overactive Bladder Syndrome (OABS)
  •   N32.8 -  Other specified disorders of bladder
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: Placebo
  •   Drug: Placebo
  •   Drug: SMP-986
end of 1:N-Block interventions
start of 1:1-Block design


  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   patient/subject, caregiver, investigator/therapist, assessor
  •   Placebo
  •   Treatment
  •   Parallel
  •   II
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Change From Baseline to Week 8 in the Number of Voids/24 Hours; time frame: 8 Weeks

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- To Assess the Safety and Tolerability of 20, 40, 80 and 120 mg SMP 986 (o.d) Following 8-weeks of Treatment in Patients With Over Active Bladder Syndrome; time frame: 8 Weeks; Treatment emergent adverse event summary

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   United States
  •   Estonia
  •   France
  •   Germany
  •   Latvia
  •   Lithuania
  •   Poland
  •   Spain
  •   United Kingdom
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   [---]*
  •   2006/12/31
  •   551
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   20   Years
  •   80   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Main Inclusion Criteria:

- Males, or females who are not of child-bearing potential

- Aged 20-80 years (inclusive) with a diagnosis of OABS based on symptomatic reporting
over a period of 6 months (micturition frequency, and urgency with or without
incontinence) prior to screening.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

Main Exclusion Criteria:

- Patients will be excluded if there is an indication of any bladder outlet obstruction
or polyuria

- Patients with the following conditions, or who have undergone the following
procedures, will be excluded:

- stress urinary incontinence

- pelvic organ prolapse ( stage 2)

- genitourinary or lower bowel surgery (within 12 months prior to screening),

- pathological conditions including poorly controlled diabetes, painful bladder
syndrome/interstitial cystitis or history of chronic urinary tract infection

- neurological conditions including multiple sclerosis, Parkinson's disease or

- Patients will also be excluded if they have an indwelling catheter or perform
intermittent self catheterisation

- Patients should not have a current or past medical condition contraindicating the use
of antimuscarinics and must have discontinued use of the following drugs:

- drugs used to treat OABS or urinary incontinence

- cholinergics

- anticholinergics

- alpha adrenergic antagonists

- opioid analgesics

- compound analgesics containing an opioid

- warfarin

- Patients with a current or past malignancy (within the last 5 years)

- Patients who have ever had a tumour affecting the genitourinary tract (not including
benign prostatic hyperplasia) will be excluded.

- Patients will be ineligible if they have a clinically significant cardiac,
neurological, hepatic, renal, respiratory, haematological or gastrointestinal
disorder (including, a significant history of constipation or an active bowel disease
e.g. inflammatory bowel disease) or any other illness which in the opinion of the
Investigator would preclude the safe or compliant participation of a subject.

- Patients will be excluded if they are unable to complete the study diary

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


  • start of 1:1-Block address primary-sponsor
    • Sunovion
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Royal Hallamshire Hospital
    • Prof C Chappel 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Royal Hallamshire Hospital
    • Prof C Chappel 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting complete, follow-up complete
  •   2008/07/01
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
The parameters in and DRKS are not identical. Therefore the data import from required adjustments. For full details please see the DRKS FAQs .
  •   5
  •   2016/01/14

* This entry means the parameter is not applicable or has not been set.